Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impediments to therapeutic advances for patients with gastroesophageal adenocarcinoma.

Translational gastroenterology and hepatology·2021
Same author

Influence of Baseline Positron Emission Tomography in Metastatic Gastroesophageal Cancer on Survival and Response to Therapy.

Oncology·2021
Same author

Chemoradiotherapy Followed by Active Surveillance Versus Standard Esophagectomy for Esophageal Cancer: A Systematic Review and Individual Patient Data Meta-analysis.

Annals of surgery·2021
Same author

Long non-coding RNAs are significantly associated with prognosis and response to therapies in gastric cancer.

Clinical and translational medicine·2021
Same author

Patient-derived cell lines and orthotopic mouse model of peritoneal carcinomatosis recapitulate molecular and phenotypic features of human gastric adenocarcinoma.

Journal of experimental & clinical cancer research : CR·2021
Same author

Recent trend in gastric cancer treatment in the USA.

Journal of cancer metastasis and treatment·2021

Related Experiment Video

Updated: May 22, 2026

Intraoperative Assessment of Resection Margins in Oral Cavity Cancer: This is the Way
04:45

Intraoperative Assessment of Resection Margins in Oral Cavity Cancer: This is the Way

Published on: May 10, 2021

Anal margin cancer: current situation and ongoing trials.

Yixing Jiang1, Jaffer A Ajani

  • 1Penn State College of Medicine, Penn State Cancer Institute, Hershey, Pennsylvania, USA.

Current Opinion in Oncology
|May 15, 2012
PubMed
Summary

Management of anal margin cancer is shifting towards organ preservation, incorporating radiation and chemoradiation. Further research is needed for consensus and new therapeutic strategies for this rare disease.

Related Experiment Videos

Last Updated: May 22, 2026

Intraoperative Assessment of Resection Margins in Oral Cavity Cancer: This is the Way
04:45

Intraoperative Assessment of Resection Margins in Oral Cavity Cancer: This is the Way

Published on: May 10, 2021

Area of Science:

  • Oncology
  • Surgical Oncology
  • Radiation Oncology

Background:

  • Anal margin cancer management has evolved over 30 years.
  • The treatment paradigm has shifted from radical surgery to organ preservation.
  • Multimodality strategies, including radiation and chemoradiation, are increasingly considered.

Purpose of the Study:

  • To summarize current treatment approaches for anal margin cancer.
  • To discuss emerging therapeutic strategies for anal margin cancer.
  • To highlight the need for a consensus approach in managing this rare condition.

Main Methods:

  • Literature review of current treatment strategies.
  • Analysis of evolving management paradigms.
  • Discussion of emerging therapeutic options.

Main Results:

  • The management of anal margin cancer has shifted from radical resection to organ preservation.
  • Multimodality strategies are frequently employed.
  • Prospective trials for optimal clinical management are currently lacking.
  • Anal margin cancer is an often overlooked topic due to its rarity.

Conclusions:

  • Squamous cell carcinoma of the anal margin has a distinct clinical course compared to anal canal cancer.
  • The biology of anal margin cancer requires further exploration and understanding.
  • A consensus approach for clinical management is needed.
  • New therapeutics should be explored for advanced-stage anal margin cancer.